Accuracy and biological variation of human serum paraoxonase 1 activity and polymorphism (Q192R) by kinetic enzyme assay

被引:83
作者
Browne, Richard W.
Koury, Stephen T.
Marion, Susan
Wilding, Gregory
Muti, Paola
Trevisan, Maurizio
机构
[1] SUNY Buffalo, Dept Biotechnol & Clin Lab Sci, Buffalo, NY 14214 USA
[2] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14214 USA
[3] SUNY Buffalo, Dept Biostat, Buffalo, NY 14214 USA
关键词
D O I
10.1373/clinchem.2006.074559
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Paraoxonase 1 (PON1) phenotype is a better predictor of atherosclerosis risk than are PON1 genetic polymorphisms alone. Larger studies are required to determine the role of PON1 and there is a need for standardized PON1 assays between laboratories. Methods: We have adapted 5 enzyme kinetic assays for high-throughput automated analysis of PON1 activity. Using different substrates and reaction conditions, we measured PON1 activity and used activity ratios to identify the PON1 Q192R genetic polymorphisms and assessed the accuracy of the genotype assignments in 79 adult study participants by comparing them with genotypes determined by AlwI restriction enzyme digestion of a 176-bp PCR amplification product from genomic DNA. Imprecision was determined using pooled serum and purified enzyme preparations. Biological variability was estimated by analysis of serial samples from 17 individuals. Variability parameters were compared with total cholesterol as a point of reference to a recognized biomarker of coronary heart disease risk. Results: Salt stimulation and inhibition ratios were 97.4% and 94.7% correct in assigning Q192R genotype, respectively. Analytical imprecision (CV) was 1.0%-3.0% for phenylacetate and paraoxon substrate assays and 3.0%-8.0% for the para-nitrophenylacetate substrate assays. Combination of the 2 ratios into a double ratio resulted in 100% correct genotype classification. Conclusion: The described methods for measurement of PON1 activity and accurate genotype assignment are rapid and have potential to facilitate the efficient investigation of PON1 status in clinical and epidemiological studies. (c) 2007 American Association for Clinical Chemistry
引用
收藏
页码:310 / 317
页数:8
相关论文
共 34 条
[1]   The Gln-Arg191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary artery disease in Finns [J].
Antikainen, M ;
Murtomaki, S ;
Syvanne, M ;
Pahlman, R ;
Tahvanainen, E ;
Jauhiainen, M ;
Frick, MH ;
Ehnholm, C .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 98 (04) :883-885
[2]   Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions - A possible peroxidative role for paraoxonase [J].
Aviram, M ;
Rosenblat, M ;
Bisgaier, CL ;
Newton, RS ;
Primo-Parmo, SL ;
La Du, BN .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (08) :1581-1590
[3]   Serum paraoxonase after myocardial infarction [J].
Ayub, A ;
Mackness, MI ;
Arrol, S ;
Mackness, B ;
Patel, J ;
Durrington, PN .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (02) :330-335
[4]  
CHARLTONMENYS V, CLIN CHEM, V52, P453
[5]   Modulation of paraoxonase (PON1) activity [J].
Costa, LG ;
Vitalone, A ;
Cole, TB ;
Furlong, CE .
BIOCHEMICAL PHARMACOLOGY, 2005, 69 (04) :541-550
[6]   The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin [J].
Davies, HG ;
Richter, RJ ;
Keifer, M ;
Broomfield, CA ;
Sowalla, J ;
Furlong, CE .
NATURE GENETICS, 1996, 14 (03) :334-336
[7]  
ECKERSON HW, 1983, AM J HUM GENET, V35, P214
[8]  
ECKERSON HW, 1983, AM J HUM GENET, V35, P1126
[9]   Proposals for setting generally applicable quality goals solely based on biology [J].
Fraser, CG ;
Petersen, PH ;
Libeer, JC ;
Ricos, C .
ANNALS OF CLINICAL BIOCHEMISTRY, 1997, 34 :8-12
[10]  
FRASER CG, 1989, CRC CRIT REV CLIN LA, P409